Thabor Therapeutics develops innovative treatments for mucosal inflammatory diseases.
Thabor Therapeutics has raised $2.0M in total funding. The most recent round was Seed. The last funding was announced in July 2022.
Thabor Therapeutics's investors include Bpifrance, AdBio partners.
Thabor Therapeutics is headquartered in Paris, France.
Thabor Therapeutics develops innovative treatments for mucosal inflammatory diseases.
Thabor Therapeutics is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Thabor Therapeutics — Funding & Investors." VCBacked, July 6, 2022, https://www.vcbacked.co/company/thabor-therapeutics. Accessed September 3, 2026.
VCBacked. (2022). Thabor Therapeutics — Funding & Investors. Retrieved September 3, 2026, from https://www.vcbacked.co/company/thabor-therapeutics
{{cite web |title=Thabor Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/thabor-therapeutics |website=VCBacked |access-date=September 3, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated